Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program

9/21/2012 6:00 AM EST

Astex Pharmaceuticals, Inc.
Press release

Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program

DUBLIN, Calif., 2012-09-21 12:00 CEST (GLOBE NEWSWIRE) -- Astex
Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the
discovery and development of novel small molecule therapeutics, today announced
that clinical development of amuvatinib (MP-470), a multi-targeted tyrosine
kinase inhibitor that inhibits the mutant forms of c-Kit and PDGFR alpha and
disrupts DNA repair likely through suppression of homologous recombination
protein Rad51, has been discontinued. 

Amuvatinib was being investigated in the Phase 2 ESCAPE (TrEatment of Small
Cell lung cancer with Amuvatinib in combination with Platinum Etoposide) study.
The study used a Simon 2-stage design with the primary objective in stage 1 of
excluding the statistical probability with 90% confidence that the drug has
less than 10% response rate in platinum refractory small cell lung cancer
(SCLC) patients. Response evaluation by RECIST criteria showed 2 partial
responses in the 21 evaluable patients of stage 1 (9.5% Response Rate). No new
safety issues were identified, and biological markers studies are ongoing.
There were several patients with prolonged stable disease. The results will be
presented in a future scientific meeting. 

"This clinical proof of concept (cPOC) amuvatinib trial was designed in two
parts to define clinical activity and confirm clinical benefit and safety in
combination with chemotherapy," said James S.J. Manuso, PhD, chairman and chief
executive officer. "We have decided to end the clinical development of
amuvatinib despite the favorable safety and preliminary clinical activity we
observed in the first stage of this Phase 2 trial and in the earlier Phase 1b
trial in combination platinum-etoposide based chemotherapy. We will consider
the possibility of licensing the compound to any partners who would be
interested in its further development." 

"Amuvatinib's performance in the clinic was promising in the Phase 1b
combination trial with DNA damaging agents," said Mohammad Azab, MD, chief
medical officer. "There is no effective treatment for SCLC patients with truly
platinum-refractory disease similar to the patients enrolled in this study.
While some clinical activity was observed, the ESCAPE study response rate in
stage 1 fell short of fully meeting our pre-specified primary endpoint.
Consistent with our corporate strategy to move into advanced clinical stages
only those agents that meet our pre-specified primary endpoints in the cPOC
stage, we decided to discontinue the internal development of this program." 

About Amuvatinib

Amuvatinib is an oral multi-targeted tyrosine kinase inhibitor which inhibits
the mutant forms of c-Kit and PDGFR alpha. It also disrupts DNA repair likely
through suppression of homologous recombination protein Rad51, an important
survival pathway in many human cancers. In vitro and in vivo data have
demonstrated amuvatinib synergy with DNA damaging agents including etoposide
and doxorubicin. Overall, in the amuvatinib clinical development program, over
200 subjects were exposed to at least one dose of amuvatinib. In the Phase 1b
clinical study in combination with carboplatin and etoposide, responses in
SCLC, neuroendocrine as well as other tumor types were observed. Human
pharmacokinetic data suggest that co-administration of amuvatinib did not alter
exposures of standard of care agents including carboplatin, etoposide,
doxorubicin, paclitaxel, topotecan or erlotinib as measured by overall
exposure. In the first-in-human study, durable clinical benefit was observed in
the gastrointestinal stromal tumors (GIST) with modulation of Rad51 observed in
skin punch biopsies. In clinical trials, amuvatinib has demonstrated a wide
therapeutic window and shows minimal toxicity in the expected therapeutic dose
range, despite suppressing several signaling pathways within cells. 

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel
small molecule therapeutics with a focus on oncology. The Company is developing
a proprietary pipeline of novel therapies and is creating de-risked products
for partnership with leading pharmaceutical companies. Astex Pharmaceuticals
developed Dacogen® (decitabine) for Injection and receives significant
royalties on global sales. 

For more information about Astex Pharmaceuticals, Inc., please visit
http://www.astx.com. 

The Astex Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=12273 


         CONTACT: Timothy L. Enns
         Astex Pharmaceuticals, Inc.
         Senior Vice President
         Corporate Communications & Marketing
         Tel:  +1 (925) 560-2810
         E-mail:   
         
         Susanna Chau
         Astex Pharmaceuticals, Inc.
         Manager
         Investor Relations
         Tel:  +1 (925) 560-2845
         E-mail:   
         
         Alan Roemer
         The Trout Group
         Managing Director
         Tel:  +1 (646) 378-2945
         E-mail:  
         
         Christine Labaree
         MacDougall Biomedical Communications
         Senior Vice President
         Tel: +1 (978) 697-8463
         E-mail: